secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093345
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.02, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma Q2 net loss $1.2M on $16.2M tax benefit; cash $212.9M; PYNNACLE Phase 2 on track
--------------------------------------------------------------------------------

- Net loss narrowed to $1.2M from $17.4M YoY due to $16.2M income tax benefit from NOL sale.
- Cash, equivalents, and marketable securities $212.9M; net cash used in operations $17.8M in H1 2024.
- Phase 2 monotherapy enrollment on track; >60% sites activated; interim analysis expected by mid-2025.
- Phase 1b rezatapopt/pembrolizumab combo adjusted to exclude KRAS SNV; DLTs observed at 1000 mg, then escalated back.
- Lease termination at Princeton HQ with $1.42M fee; relocation to smaller space to reduce costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000095017024093345/0000950170-24-093345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000095017024093345/pmvp-20240805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer